NCT00948064 - Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

September 8, 2009

Primary Completion Date

April 30, 2015

Study Completion Date

August 3, 2017

Conditions

Leukemia

Interventions

DRUG

Vorinostat

200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)

DRUG

Azacitidine

75 mg/m\^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston